Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TDP1 | Q9NUW8 | 5/20 | 0.44 |
| ▸ | MEN1 | O00255 | 1/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.43 |
| ▸ | MAPT | P10636 | 1/20 | 0.43 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.43 |
| ▸ | GPR35 | Q9HC97 | 2/20 | 0.42 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.41 |
| ▸ | TSHR | P16473 | 1/20 | 0.41 |
| ▸ | CES2 | O00748 | 3/20 | 0.40 |
| ▸ | CES1 | P23141 | 2/20 | 0.40 |
| ▸ | CHRNB2 | P17787 | 1/20 | 0.39 |
| ▸ | CHRNA4 | P43681 | 1/20 | 0.39 |
| ▸ | ACHE | P22303 | 1/20 | 0.39 |
| ▸ | AKR1C3 | P42330 | 1/20 | 0.39 |
| ▸ | AKR1C1 | Q04828 | 1/20 | 0.39 |
| ▸ | POLB | P06746 | 1/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.37 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.37 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.37 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1080845 | 1.00 | TDP1 (0.44) | TDP1MEN1KMT2AMAPTNPSR1 | |
| Hydrochloric Acid SCHEMBL7214642 | 0.98 | TDP1 (0.43) | TDP1MEN1KMT2AMAPTNPSR1 | |
| Hydrochloric Acid SCHEMBL7214648 | 0.98 | TDP1 (0.43) | TDP1MEN1KMT2AMAPTNPSR1 | |
| SCHEMBL7214637 | 0.86 | CHRNB2 (0.41) | TDP1MAPTGPR35L3MBTL1TSHR | |
| SCHEMBL7517485 | 0.86 | TDP1 (0.41) | TDP1MEN1KMT2AGPR35L3MBTL1 | |
| SCHEMBL1082453 | 0.82 | MAPT (0.48) | TDP1MEN1KMT2AMAPTNPSR1 | |
| SCHEMBL5916971 | 0.79 | GPR35 (0.46) | TDP1MEN1KMT2AMAPTGPR35 | |
| SCHEMBL14651332 | 0.78 | HRH4 (0.46) | L3MBTL1ALDH1A1 | |
| SCHEMBL1080847 | 0.78 | GPR35 (0.39) | TDP1MEN1KMT2AMAPTGPR35 | |
| SCHEMBL11444096 | 0.76 | TDP1 (0.42) | TDP1MEN1KMT2AMAPTGPR35 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 23 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4703350-A1 | METHOD FOR PREPARING 4-AMINOINDAN AND METHOD FOR PREPARING DIHYDROINDENYL-PYRAZOLO[3,4-B]PYRIDINE-AMINE | JW Pharmaceutical Corporation (KR) | 2026-03-04 | — | — | EP | disclosed |
| WO-2024224297-A1 | METHOD FOR PREPARING 4-AMINOINDAN AND METHOD FOR PREPARING DIHYDROINDENYL-PYRAZOLO[3,4-B]PYRIDINE-AMINE | 제이더블유중외제약 주식회사 | 2024-10-31 | — | — | WO | disclosed |
| WO-2019193541-A1 | BICYCLIC AROMATIC RING DERIVATIVES OF FORMULA (I) AS ATF4 INHIBITORS | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2019-10-10 | — | — | WO | disclosed |
| WO-2019193541-A1 | BICYCLIC AROMATIC RING DERIVATIVES OF FORMULA (I) AS ATF4 INHIBITORS | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2019-10-10 | — | — | WO | disclosed |
| US-8987256-B2 | Oxo-heterocyclic substituted carboxylic acid derivatives and the use thereof | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2015-03-24 | — | — | US | disclosed |
| US-8987256-B2 | Oxo-heterocyclic substituted carboxylic acid derivatives and the use thereof | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2015-03-24 | — | — | US | disclosed |
| US-8987256-B2 | Oxo-heterocyclic substituted carboxylic acid derivatives and the use thereof | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2015-03-24 | — | — | US | disclosed |
| CN-102083803-B | Oxocyclic substituted carboxylic acid derivatives and their use | BAYER IP GMBH | 2015-02-18 | — | — | CN | disclosed |
| EP-2268625-B1 | OXO-HETEROCYCLIC SUBSTITUTED CARBOXYLIC ACID DERIVATES AND THE USE THEREOF | Bayer Pharma AG (DE) | 2012-05-16 | — | — | EP | disclosed |
| CN-101331122-B | Salts of modulators of PPAR and methods of treating metabolic disorders | KALYPSYS INC | 2011-09-07 | — | — | CN | disclosed |
| US-20110034450-A1 | OXO-HETEROCYCLIC SUBSTITUTED CARBOXYLIC ACID DERIVATIVES AND THE USE THEREOF | BAYER SCHERING PHARMA AKTIEGESELLSCHAFT (DE) | 2011-02-10 | — | — | US | disclosed |
| US-20110034450-A1 | OXO-HETEROCYCLIC SUBSTITUTED CARBOXYLIC ACID DERIVATIVES AND THE USE THEREOF | BAYER SCHERING PHARMA AKTIEGESELLSCHAFT (DE) | 2011-02-10 | — | — | US | disclosed |
| US-20110034450-A1 | OXO-HETEROCYCLIC SUBSTITUTED CARBOXYLIC ACID DERIVATIVES AND THE USE THEREOF | BAYER SCHERING PHARMA AKTIEGESELLSCHAFT (DE) | 2011-02-10 | — | — | US | disclosed |
| EP-1866292-B1 | TRICYCLIC 1,2,4-TRIAZINE OXIDES AND COMPOSITIONS THEREFROM FOR THERAPEUTIC USE IN CANCER TREATMENTS | AUCKLAND UNISERVICES LTD (NZ) | 2010-12-15 | — | — | EP | disclosed |
| WO-2009127338-A1 | OXO-HETEROCYCLIC SUBSTITUTED CARBOXYLIC ACID DERIVATES AND THE USE THEREOF | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2009-10-22 | — | — | WO | disclosed |
| US-20090186886-A1 | Tricyclic 1,2,4-Triazine Oxides and Compositions for Therapeutic Use in Cancer Treatments | AUCKLAND UNISERVICES LIMITED (NZ) | 2009-07-23 | — | — | US | disclosed |
| US-20090186886-A1 | Tricyclic 1,2,4-Triazine Oxides and Compositions for Therapeutic Use in Cancer Treatments | AUCKLAND UNISERVICES LIMITED (NZ) | 2009-07-23 | — | — | US | disclosed |
| CN-101331122-A | Salts of modulators of PPAR and methods of treating metabolic disorders | KALYPSYS INC (US) | 2008-12-24 | — | — | CN | disclosed |
| US-7439356-B2 | Substituted indan derivatives | ASTRAZENECA AB (SE) | 2008-10-21 | — | — | US | disclosed |
| US-20070149545-A1 | Substituted indan derivatives | BERG STEFAN | 2007-06-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070149545-A1 | Substituted indan derivatives | CBR3, CORO1C, REL | TDP1 4793/4885MEN1 4063/4885KMT2A 2881/4885 |
| US-20110034450-A1 | OXO-HETEROCYCLIC SUBSTITUTED CARBOXYLIC ACID DERIVATIVES AND THE USE THEREOF | OTC, PC, HCAR2 | TDP1 2881/4885MEN1 3585/4885KMT2A 2766/4885 |
| US-20090186886-A1 | Tricyclic 1,2,4-Triazine Oxides and Compositions for Therapeutic Use in Cancer Treatments | HIF1AN, HIF1A, HYOU1 | TDP1 1067/4885MEN1 3240/4885KMT2A 1065/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.